Marcus Schindler - Novo Nordisk Head EVP

NOVA Stock  EUR 100.00  0.50  0.50%   

Insider

Marcus Schindler is Head EVP of Novo Nordisk AS
Age 57
Phone45 44 44 88 88
Webhttps://www.novonordisk.com

Novo Nordisk Management Efficiency

The company has return on total asset (ROA) of 0.2169 % which means that it generated a profit of $0.2169 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.72 %, meaning that it generated $0.72 on every $100 dollars invested by stockholders. Novo Nordisk's management efficiency ratios could be used to measure how well Novo Nordisk manages its routine affairs as well as how well it operates its assets and liabilities.
Novo Nordisk AS has accumulated 20.77 B in total debt with debt to equity ratio (D/E) of 9.1, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Novo Nordisk AS has a current ratio of 0.94, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Novo Nordisk until it has trouble settling it off, either with new capital or with free cash flow. So, Novo Nordisk's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Novo Nordisk AS sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Novo to invest in growth at high rates of return. When we think about Novo Nordisk's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Shannon KlingerModerna
52
Torsten LeueTalanx AG
57
Erik WiklundSIVERS SEMICONDUCTORS AB
49
Jorg BurzerMercedes Benz Group AG
53
Sylke MaasBioNTech SE
N/A
Jerh CollinsModerna
N/A
Markus SchaferMercedes Benz Group AG
58
Thomas LaubertMercedes Benz Group AG
50
Ray JordanModerna
N/A
Caroline SchlienkampTalanx AG
49
Sven PetterssonSIVERS SEMICONDUCTORS AB
60
Stephen BerensonModerna
58
Juan AndresModerna
58
Sierk PoettingBioNTech SE
50
Robert GreenSIVERS SEMICONDUCTORS AB
60
Patric ErlandssonSIVERS SEMICONDUCTORS AB
51
Edgar PulsTalanx AG
50
Britta SeegerMercedes Benz Group AG
54
James MockModerna
46
Christopher LohmannTalanx AG
55
Ozlem MDBioNTech SE
56
Novo Nordisk AS, a healthcare company, engages in the development, manufacture, and marketing of pharmaceutical products worldwide. The company was founded in 1925 and is headquartered in Bagsvaerd, Denmark. NOVO NORDISK is traded on Frankfurt Stock Exchange in Germany. Novo Nordisk AS (NOVA) is traded on Frankfurt Exchange in Germany and employs 54,393 people.

Management Performance

Novo Nordisk AS Leadership Team

Elected by the shareholders, the Novo Nordisk's board of directors comprises two types of representatives: Novo Nordisk inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Novo. The board's role is to monitor Novo Nordisk's management team and ensure that shareholders' interests are well served. Novo Nordisk's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Novo Nordisk's outside directors are responsible for providing unbiased perspectives on the board's policies.

Novo Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Novo Nordisk a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Currently Active Assets on Macroaxis

Additional Information and Resources on Investing in Novo Stock

When determining whether Novo Nordisk AS offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Novo Nordisk's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Novo Nordisk As Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Novo Nordisk As Stock:
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novo Nordisk AS. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.
You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Please note, there is a significant difference between Novo Nordisk's value and its price as these two are different measures arrived at by different means. Investors typically determine if Novo Nordisk is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Novo Nordisk's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.